Abstract
In the Western world one in three people will develop a malignancy, and of these two-thirds can be expected ultimately to die of their cancer. Figures from 1980 for the European Community countries estimate 1 220 000 incident cases of cancer and 750 000 deaths. Death from cancer is usually due to the development of metastases, and the skeleton is the organ most frequently involved.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Galasko CSB (1981) The anatomy and pathways of skeletal metastases. In: Weiss L, Gilbert AH (eds) Bone metastasis. Hall, Boston, pp 49–63
Scher HI, Yagoda A (1987) Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am. J. Med. 82 [Suppl 2A]: 6–28
Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Br. J. Cancer 55: 61–66
Dorudi S, Hart I (1993) Mechanisms underlying invasion and metastasis. Curr Opin Oncol 5: 130–135
Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumour emboli labelled with 125I-5-iodo-2’-deoxyuridine. J Natl Cancer Inst 45: 773–782.
Boyce BF (1991) Normal bone remodelling and its disruption in metastatic bone disease. In: Rubens RD, Fogelman I (eds) Bone metastasis - diagnosis and treatment. Springer, Berlin, Heidelberg, New York, pp 11–30
Ewing J (1928) Metastasis. In: Neoplastic diseases. A textbook on tumours. Saunders, Philadelphia, pp 77–89
Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet I: 571–573
Batson OV (1942) The role of the vertebral veins in metastatic processes. Ann Intern Med 16: 38–45
Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G (1992) Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689
Mansi JL, Berger U, Easton D, McDonnell T, Redding WH, Gazet JC et al. (1987) Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J 29: 1093–1096
Mundy GR, De Martino S, Rowe DW (1981) Collagen and collagen-derived fragments are chemotactic for tumour cells. J. Clin. Invest. 68: 1102–1105
Orr FW, Varani J, Gondek MD, Ward PA, Mundy GR (1980) Partial characterization of a bone-derived chemotactic factor for tumour cells. Am J. Pathol. 99: 43–52
Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG (1991) Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br. Med. J. 303: 1506–1509
Chackal-Roy M, Niemeyer C, Moore M, Zetter BR (1989) Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J. Clin. Invest. 84: 43–50
Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel ME (1988) Altered expression of nm23, a gene associated with low tumour metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 48: 6550–6554
Henneesy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TWJ (1991) Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 83: 281–285
Nesbit RM, Baum WC (1984) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JNCI 68: 507–517
Jacobs SC, Pikna D, Lawson RK (1979) Prostatic osteoblastic factor. Invest. Urol. 17: 195–198
Brookes M (1971) Blood vessels in bone marrow. In: Brookes M (ed) The blood supply of bone. An approach to bone biology. Butterworth, London, pp 67–91
Boxer DI, Todd CEC, Coleman R, Fogelman I (1989) Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 30: 1318–1320
Coleman RE, Purohit OP (1993) Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev 19: 79–103
Koutsilieris M, Rabbini SA, Bennett HPJ et al. (1987) Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J. Clin. Invest. 80: 941–946
Galasko CSB (1976) Mechanisms of bone destruction in the development of skeletal metastases. Nature 263: 507–508
Dodwell D, Howell A (1991) The systemic treatment of bone metastases. In: Rubens RD, Fogelman I (eds) Bone metastases - diagnosis and treatment. Springer, Berlin, Heidelberg, New York, pp 121–148
Charbord P, L’héritier C, Cukerstein W, Lumbroso J, Tubiana M (1977) Radio- iodine treatment in differentiated thyroid carcinomas. Treatment of first local recurrences and of bone and lung metastases. Ann Radiol 20: 783–786
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Coleman, R. (1994). Incidence and Distribution of Bone Metastases. In: Diel, I.J., Kaufmann, M., Bastert, G. (eds) Metastatic Bone Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78596-2_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-78596-2_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-57356-2
Online ISBN: 978-3-642-78596-2
eBook Packages: Springer Book Archive